LADEL, CHRISTOPH H.,GUEHRING, HANS,BAY-JENSEN, ANNE-CHRISTINE,KARSDAL, MORTEN,QVIST, PER
申请号：
CA3075713
公开号：
CA3075713A1
申请日:
2018.09.28
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.
